<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03319849</url>
  </required_header>
  <id_info>
    <org_study_id>NTMT-03-B</org_study_id>
    <nct_id>NCT03319849</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2</brief_title>
  <official_title>A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurotech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurotech Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety
      of the Renexus® implants in participants with macular telangiectasia type 2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">October 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 16, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Ellipsoid Zone (EZ)</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Mean change in EZ as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Macular Thickness</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Renexus® compared to sham relative to mean change in central macular thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Eyes with &gt;35% Increase in EZ Break Area</measure>
    <time_frame>From baseline at month 24.</time_frame>
    <description>Renexus ® compared to sham relative to proportion of eyes with &gt;35% increase in EZ break area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Aggregate Sensitivity of Microperimetry</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Renexus ® compared to sham relative to mean change in aggregate sensitivity of microperimetry within the EZ line break area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Reading Speed</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Renexus® compared to sham relative to mean change in reading speed assessed using Internal Reading Speed Texts (IReST) cards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Eye Institute-Visual Function Questionnaire (NEI-VFQ)</measure>
    <time_frame>Baseline through 24 months.</time_frame>
    <description>Renexus® compared to sham relative to mean change in the NEI-VFQ near activities subscale score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Macular Telangiectasia Type 2</condition>
  <arm_group>
    <arm_group_label>Renexus®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Renexus®</intervention_name>
    <description>Surgery to receive one Renexus® device implant.</description>
    <arm_group_label>Renexus®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Non-penetrating sham procedure to mimic implant procedure.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Participant must have at least one study eye with a positive diagnosis of MacTel Type
             2

          -  Participant must have an Inner Segment - Outer Segment Junction Line (IS/OS) Photo
             Receptor (PR) break in the study eye(s) and en face EZ (area of IS/OS loss) as
             measured by spectral-domain optical coherence tomography (SDOCT) between 0.16 mm^2 and
             2.00 mm^2

          -  Participant's best corrected visual acuity is 54 letter score or better (20/80 or
             better) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart

        Key Exclusion Criteria:

          -  Participant received intravitreal steroid therapy for non-neovascular MacTel within
             the last 3 months

          -  Participant has ever received intravitreal anti-vascular endothelial growth factor
             (VEGF) therapy for neovascular disease complicating MacTel in either eye

          -  Participant has evidence of ocular disease other than MacTel that, in the judgment of
             the examining physician, may confound the diagnosis, procedures or outcome of the
             study

          -  Participant was a study participant in any other clinical trial of an intervention
             (drug or device) within the last 6 months

          -  Participant is pregnant or breastfeeding

          -  Participant has a chronic requirement (eg ≥ 4 weeks at a time) for ocular medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Johnson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Neurotech Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Halter</last_name>
    <phone>401-333-3880</phone>
    <phone_ext>3145</phone_ext>
    <email>b.halter@neurotechusa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami-Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip J. Rosenfeld, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong Yan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University, Department of Ophthalmology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amani Fawzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grant M. Comer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Center of New Jersey, LLC</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Higgins, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Northwest, P.C. - Sylvan</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael S. Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Brucker, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Research Center, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian B. Berger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydney Eye Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Gillies</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Victorian Eye and Ear Hospital Research and Ethics Committee</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robyn Guymer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciliary Neurotrophic Factor (CNTF)</keyword>
  <keyword>Macular Telangiectasia (MacTel)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

